Stroke RSS Page 3

Filtered By:
Specialty: Cardiology
Countries: Australia Health

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Stroke Risk Stratification: CHA2DS2-VA or CHA2DS2-VASc?
It is with interest that we note the letter by Drs Overvad and colleagues in which concern is expressed regarding a newly proposed strategy in the recently published Australian Guidelines for Atrial Fibrillation (AF) [1]. Specifically we recommend that female sex category be dropped from the CHA2DS2-VASc score; therefore recommending a CHA2DS2-VA score.
Source: Heart, Lung and Circulation - March 30, 2019 Category: Cardiology Authors: David Brieger, Cia Connell, Ben Freedman Tags: Letter to the Editor Source Type: research

Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines
Publication date: May 2019Source: Canadian Journal of Cardiology, Volume 35, Issue 5Author(s): Marco Proietti, Deirdre A. Lane, Giuseppe Boriani, Gregory Y.H. LipAbstractIn recent years the management of atrial fibrillation patients has progressively and substantially changed because of the introduction of new treatments and the availability of new data regarding the epidemiology and clinical management of these patients. In the past 2 years alone, there have been 7 new guidelines or guideline updates that have been published, which have introduced new recommendations and significantly revised previously published ones. Tw...
Source: Canadian Journal of Cardiology - April 27, 2019 Category: Cardiology Source Type: research

First Australian Experience with Total Thoracoscopic Left Atrial Appendage Occlusion with Atriclip PRO2 device
We describe the first Australian series of totally thoracoscopic external LAA occlusion with the Atriclip PRO2TM device.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: P. Joshi, P. Sadlier, R. Weerasooriya, D. Playford Tags: 466 Source Type: research

Trends in the Use of Warfarin and Novel Oral Anticoagulants in Australia, 2013 to 2017
Background: In 2013, novel oral anticoagulants (NOACs) were added to the PBS as alternatives to warfarin for stroke prevention in atrial fibrillation (AF). Aim of this study is to examine changes in the use of oral anticoagulants (OACs) since the introduction of NOACs.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: A. Dina, T. Akindele Tags: 231 Source Type: research

Revascularization Strategies in Patients With STEMI: Culprit-Only vs Multivessel Revascularization Using Percutaneous Coronary Intervention.
CONCLUSIONS: The relative frequency of multivessel vs culprit-only PCI has not changed from 2009-2015. Index complete revascularization for STEMI-MVD patients is more likely to be performed in those with worse presentations and is associated with worse in-hospital complications. PMID: 31303602 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - July 17, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Cardiac Rehabilitation and Secondary Prevention Roundtable: Australian Implementation and Research Priorities
Cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death and disease burden globally [1]. CVD resulted in>1.1 million hospitalisations in 2015-16, and incurs the highest level of health care sector expenditure in Australia (11-12% of total health expenditure) [2]. CHD accounts for the greatest single disease morbidity (>500,000 bed-days annually) and nearly one fifth of all deaths with a total cost of $1.14 billion annually [2]. Over 65,000 Australians experience an acute coronary event (heart attack or unstable angina) each year [3], and, importantly, around a third of...
Source: Heart, Lung and Circulation - February 28, 2020 Category: Cardiology Authors: Julie Redfern, Gemma Figtree, Clara Chow, Garry Jennings, Tom Briffa, Robyn Gallagher, Rachelle Foreman, on behalf of Roundtable Attendees Tags: Editorial Source Type: research

Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia
Anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but under-prescribing in eligible patients has been commonly reported. Introduction of the direct acting oral anticoagulants (DOACs) was considered to potentially improve prescribing due to increased anticoagulant options. At the time of release to the Australian market, there were limited studies investigating anticoagulant usage during hospitalisations for AF. Therefore, the aim of this study was to investigate prescribing of oral anticoagulants during hospitalisation admissions for AF during the time of DOAC introduction to the Australian market.
Source: Heart, Lung and Circulation - March 31, 2020 Category: Cardiology Authors: Iniya Rathinam, Shailendra Anoopkumar-Dukie, Tony Badrick, Trudy Teasdale, Nijole Bernaitis Tags: Original Article Source Type: research

692 Anticoagulation Prescription for Indigenous and Non-Indigenous Patients With Atrial Fibrillation in Central Australia
This study sought to compare anticoagulant prescribing practices in Indigenous and non-Indigenous Australians with AF in Central Australia.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: N. Clarke, C. Gallagher, B. Pitman, S. Tu, N. Hanna-Rivero, N. Kangaharan, K. Roberts-Thomson, D. Lau, R. Mahajan, P. Sanders, C. Wong Source Type: research

516 Non-Vitamin K Anticoagulation for Non-Valvular Atrial Fibrillation in Regional Australia
Non-vitamin K antagonist oral anticoagulants (NOACs) are the therapy of choice for stroke prevention in patients with non-valvular atrial fibrillation and at least one risk factor. The Illawarra-Shoalhaven region local health district provides health services for around 400,000 people. In regional centres, many AF patients are managed by GPs. The purpose of this study was to identify the proportion of patients with NVAF who were prescribed different NOACs as well as determine if the dosage follows current guidelines.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: J. Moragues Source Type: research

The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention
Objective The aim of the review was to assess whether CHA2DS2-VASc score is predictive of mortality in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). Background The CHA2DS2-VASc score is validated in predicting stroke risk in atrial fibrillation. The optimum management strategy for these patients undergoing PCI is still debated. Methods The CHA2DS2-VASc score was calculated in consecutive patients with atrial fibrillation undergoing PCI in a large Australian registry between 2007 and 2013. Patients were divided into low (1–2), intermediate (3–4) and high (≥5) ...
Source: Coronary Artery Disease - May 6, 2021 Category: Cardiology Tags: PCI/Coronary Angiography Source Type: research

Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study
Conclusions Use of secondary prevention therapies diminishes over time following an ACS. Patients receiving secondary prevention had decreased rates of death and MACE at 2 years.
Source: Heart Asia - January 12, 2019 Category: Cardiology Authors: Chow, C. K., Brieger, D., Ryan, M., Kangaharan, N., Hyun, K. K., Briffa, T., for the CONCORDANCE Investigators, Brieger, Xu, Kilian, Myers, Parkin, Morrison, Rajaratnam, Tattam, Waites, Baldo, Kamaladasa, Davies, Collins, Nyman, Blenkhorn, Boys, Juergens, Tags: Open access Original research Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE) is a double-blind, randomised controlled trial (RCT) of PPV in preventing ischaemic events. Participants received PPV or placebo once at baseline and are being followed-up for incident fatal and non-fatal myocardial infarction or stroke over 6 years.
Source: Atherosclerosis - March 5, 2022 Category: Cardiology Authors: Shu Ren, Philip M. Hansbro, Wichat Srikusalanukul, Jay C. Horvat, Tegan Hunter, Alexandra C. Brown, Roseanne Peel, Jack Faulkner, Tiffany-Jane Evans, Shu Chuen Li, David Newby, Alexis Hure, Walter P. Abhayaratna, Sotirios Tsimikas, Ayelet Gonen, Joseph L. Source Type: research

Pages: 1 2 3 4